NCT06595563 2026-02-19
ZEPHIR-02
Jules Bordet Institute
Phase 2 Recruiting
Clinical Trials
4 trialsNCT03417544 2025-04-02
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06278870 2024-02-26
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT04385563 2020-05-13
A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown